FDA Approves Two New Indications for Merck?s KEYTRUDA (pembrolizumab)
KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS =1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression
- KEYTRUDA 200 mg intravenously every three weeks;
- KEYTRUDA 200 mg intravenously every three weeks, carboplatin AUC 5 mg/mL/min intravenously every three weeks or cisplatin 100 mg/m2?intravenously every three weeks and FU 1000 mg/m2/day as a continuous intravenous infusion over 96 hours every three weeks (maximum of six cycles of platinum and FU);
- Cetuximab 400 mg/m2?intravenously as the initial dose then 250 mg/m2?intravenously once weekly, carboplatin AUC 5 mg/mL/min intravenously every three weeks or cisplatin 100 mg/m2?intravenously every three weeks and FU 1000 mg/m2/day as a continuous intravenous infusion over 96 hours every three weeks (maximum of six cycles of platinum and FU).
Endpoint | CPS =1 | CPS =20 | ||||||||||
KEYTRUDA
200 mg every 3 weeks n=257 |
Cetuximab
Platinum FU n=255 |
KEYTRUDA
200 mg every 3 weeks n=133 |
Cetuximab
Platinum FU n=122 |
|||||||||
OS | ||||||||||||
Number of events (%) | 177 (69%) | 206 (81%) | 82 (62%) | 95 (78%) | ||||||||
Median in months (95% CI) | 12.3
(10.8, 14.9) |
10.3 (9.0,11.5) | 14.9
(11.6, 21.5) |
10.7
(8.8, 12.8) |
||||||||
Hazard ratio* (95% CI) | 0.78 (0.64, 0.96) | 0.61 (0.45, 0.83) | ||||||||||
p-Value? | 0.0171 | 0.0015 | ||||||||||
PFS | ||||||||||||
Number of events (%) | 225 (88%) | 231 (91%) | 113 (85%) | 111 (91%) | ||||||||
Median in months (95% CI) | 3.2 (2.2, 3.4) | 5.0 (4.8, 5.8) | 3.4 (3.2, 3.8) | 5.0 (4.8, 6.2) | ||||||||
Hazard ratio??(95% CI) | 1.15 (0.95, 1.38) | 0.99 (0.75, 1.29) | ||||||||||
Objective Response Rate | ||||||||||||
ORR??(95% CI) | 19%
(14.5, 24.4) |
35%
(29.1, 41.1) |
23%
(16.4, 31.4) |
36%
(27.6, 45.3) |
||||||||
Complete response rate | 5% | 3% | 8% | 3% | ||||||||
Partial response rate | 14% | 32% | 16% | 33% | ||||||||
Duration of Response | ||||||||||||
Median in months (range) | 20.9
(1.5+, 34.8+) |
4.5
(1.2+, 28.6+) |
20.9
(2.7, 34.8+) |
4.2
(1.2+, 22.3+) |
||||||||
* Based on the stratified Cox proportional hazard model
??Based on a stratified log-rank test ??Response: Best objective response as confirmed complete response or partial response |
||||||||||||
Endpoint | KEYTRUDA
200 mg every 3 weeks Platinum FU n=281 |
Cetuximab
Platinum FU n=278 |
||||
OS | ||||||
Number (%) of patients with event | 197 (70%) | 223 (80%) | ||||
Median in months (95% CI) | 13.0
(10.9, 14.7) |
10.7
(9.3, 11.7) |
||||
Hazard ratio* (95% CI) | 0.77 (0.63, 0.93) | |||||
p-Value? | 0.0067 | |||||
PFS | ||||||
Number of patients with event (%) | 244 (87%) | 253 (91%) | ||||
Median in months (95% CI) | 4.9 (4.7, 6.0) | 5.1 (4.9, 6.0) | ||||
Hazard ratio* (95% CI) | 0.92 (0.77, 1.10) | |||||
p-Value? | 0.3394 | |||||
Objective Response Rate | ||||||
ORR??(95% CI) | 36%
(30.0, 41.5) |
36%
(30.7, 42.3) |
||||
Complete response rate | 6% | 3% | ||||
Partial response rate | 30% | 33% | ||||
Duration of Response | ||||||
Median in months (range) | 6.7
(1.6+, 30.4+) |
4.3
(1.2+, 27.9+) |
||||
* Based on the stratified Cox proportional hazard model
??Based on stratified log-rank test ??Response: Best objective response as confirmed complete response or partial response |
||||||
- stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
- metastatic.
Share this article on WhatsApp, LinkedIn and Twitter
Incisive News in 3 Shots.
Contact Us
- First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
- +91-120 428 0707
- connect@pharmashots.com
- Newsletter